الصفحة 1
الصفحة 1
Medicinal plants and antimicrobial therapies
Serves as an excellent comprehensive material covering the current understandings and updates on antimicrobial resistance (AMR) and the use of medicinal plant resources for tackling it. Chapters cover important aspects of AMR and strategies to address this threatening issue with medicinal plants and their resources. One health perspectives for addressing AMR have been presented for the readers. Antimicrobial medicinal plant therapeutic resources including crude extracts, active fractions, pure molecules and essential oils, besides using them as functionalizing agents for nano-antimicrobials have been covered. Further, plant endophytes as a source of antimicrobial compounds have been discussed. Chapters cover both the bactericidal as well as resistance-reversal (or potentiating/ combinatorial therapies) potencies of medicinal plant resources. The book also focuses on how medicinal plant resources effectively target major determinants of AMR.
Medical biotechnology, biopharmaceutics, forensic : science and bioinformatics
Covers a range of topics on exploiting Nigeria’s mega biodiversity for food security and health; DNA forensic science and its applications; medical biotechnology and biopharmaceutics; medicinal and underutilized plants; impact and mitigation of antibiotic resistance; bioinformatics applications; medical insect biotechnology; etc. The book will be useful reference material for the scientists and researchers working in the fields of nutraceuticals, molecular diagnostics and DNA forensics, biopharmaceuticals and medical biotechnology, nanotechnology, antimicrobials from indigenous plant species, bioinformatics, etc.
Infection Control in the Intensive Care Unit
Infection Control in the Intensive Care Unit has been entirely rewritten in this second edition. All statements are justified by the best available evidence, avoiding unsubstantiated expert opinion. The book contains a new section dedicated to the microbiology of the critically ill, specifically, how to process and interpret surveillance cultures to distinguish the ‘normal’ from the ‘abnormal’ carrier state. There are five totally new chapters dealing with evidence-based infection control molecular techniques for outbreak analysis; clinical virology in neonatal, paediatric and adult intensive care; the six basic principles of the therapy of an infection; and the role of the pharmacist in infection control. Attention is given to special topics such as nutrition, gut mucosal protection and the control of antimicrobial resistance. The addition of enteral to parenteral antimicrobials contributes to the control of multi-resistant micro-organisms. This completely revised second edition is a ‘must have’ for anyone requiring in depth knowledge in the ever expanding field of infection control.
Drug repurposing : A new fashion for a new hope
The repurposing of drugs is becoming increasingly attractive as it avoids the long process and cost implications associated with bringing a novel drug to market i.e., drug repurposing is cost effective and time saving. This study will discuss the repositioning of several drugs that belong to different pharmaceutical classifications such as antimicrobials (itraconazole and fluoroquinolones), anti-diabetic agents (metformin and sodium glucose co-transporter 2 inhibitors), cardiovascular drugs (β-blockers and digoxin), anticonvulsants (topiramate), immunosuppressants (sirolimus), non-steroidal anti-inflammatory drugs (NSAIDs e.g., COX inhibitors), and cholesterol lowering drugs (statins).
Drug interactions in infectious diseases : Mechanisms and models of drug interactions
Provides a comprehensive review of basic clinical pharmacology with a focus on metabolism and transporter-mediated drug interactions. The chapters address materials that cannot be retrieved easily in the medical literature, including materials focused on the complex interrelationship of acute infection, inflammation, and the risk of drug interactions in the Drug-Cytokine chapter. The Food-Drug and Herb-Drug interactions chapters remain definitive resources. A new chapter on in vitro modeling of drug interactions is included along with updates on design and data analysis of clinical drug interaction studies. Authoritative discussion of models for regulatory decision-making on drug-drug interactions provides the necessary framework to aid antimicrobial drug development. This concise review of the mechanisms and models of drug interactions provides important insights to health care practitioners as well as scientists in drug development
Drug interactions in infectious diseases : Antimicrobial drug interactions
Delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
Community-Acquired Pneumonia
Community-acquired pneumonia (CAP) is a disease associated with high morbidity and mortality, with at least one third of cases requiring hospitalization, exceeding the numbers admitted for myocardial infarction and stroke. Despite a broad armamentarium of antimicrobials available, it remains an important cause of death in industrialized countries. CAP is caused by a variety of pathogens with their order of importance dependent on the location and population studied. Despite the importance of CAP, reliable data and a recommended evidence-based therapy are lacking, and basic research must be improved. The goal of this volume is to present state-of-the-art knowledge on epidemiology, clinical presentation, immunology, pathology, and diagnosis including the identification of "new pathogens". Therapeutic approaches, antibiotics resistance, disease management and vaccination strategies are also covered. The volume is of interest to researchers and clinicians in virology, epidemiology and biomedicine.
Bacteriocins : Ecology and Evolution
Microbes produce an extraordinary array of defense systems. These include bacteriocins, a class of antimicrobial molecules with narrow killing spectra, produced by bacteria. The book describes the diversity and ecological role of bacteriocins of Gram-positive and Gram-negative bacteria, presenting a new classification scheme for the former and a state-of-the-art look at the role of bacteriocins in bacterial communication. It discusses the molecular evolution of colicins and colicin-like bacteriocins, and provides a contemporary overview of archaeocins, bacteriocin-like antimicrobials produced by archaebacteria. Furthermore, various modeling (in silico) studies elucidate the role of bacteriocins in microbial community dynamics and fitness, delving into rock-paper-scissors competition and the counter-intuitive survival of the weakest. The book makes compelling reading for a multi-faceted scientific audience, including those working in the fields of biodiversity and biotechnology, notably in the human and animal health domain.
Advances in endodontics and periodontics
Aims to improve the state of the art in relation to the most relevant advances in Endodontics and Periodontics. Topics addressed in this Special Issue include alternative treatment strategies such as “green” antimicrobials, the relationship with systemic diseases, new devices and materials which enable a reduction in therapy failures, as well as updating evidence-based knowledge pertaining to endodontics and periodontics.
